
Deals & Capital Markets
Pfizer Licenses Novavax's Matrix-M Adjuvant for Up to $530M
Jan 20
You're signed outSign in or to get full access.

View earnings summary and analysis
View earnings summary and analysis
View earnings summary and analysis
View earnings summary and analysis
View earnings summary and analysis
Research analysts covering PFIZER.



